Ann: Change of Director's Interest Notice , page-10

The title of this thread is a very apt description of the CXS directors attitude - change of interest (as in we lost interest).

Directors incapable of taking the company to the summit of the mountain.

Incompetent in managing a successful FDA drug approval.
Unable to deliver a proper return to those who funded the party along the way - CXS shareholders.

I first invested in this company in the dark ages, when Chemgenex was known as Autogen (ASX:AGT). Later, about eight years or so ago, the name was changed to AGT Biosciences.

At the time of that name change, CEO Greg Collier had this to say:
"It's the culmination of the repackaging of the company"
"We decided rebranding would help investors focus on the changes rather than the old management"

>>investors focus on the changes rather than the old management<<

Perhaps we should all have paid more attention to the quality of the management, including Collier.

He has been very successful in loading his personal account with low-ball options at the expense of the ordinary shareholders and now he (and his fellow directors) is chucking in the CXS towel.

Well done Greg, We now know why we should have focused more on the quality of management and less on a name change.